‘Moderna and Pfizer are in talks with the US on H5N1 bird flu vaccines.
Following the news, analysts at Jefferies put the Moderna stock move down to a flurry of events, including the Q1 beat, the short covering and unwind, the soon-to-come RSV FDA decision, ASCO PCV updates soon, and now public attention to any upside from Avian flu cases and/or any stockpile deals.
“These are all in play in the near-term while fundamentally – we’re also focused on RSV approval, ACIP meeting in June and important IMS script data,” said the firm.’
h/t A Deplorable Neanderthal
Views:
171